Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$41.18 ▼ -0.27
(-0.65%)
MKT CAP: $1.92B • VOL: 343.9K
52W L $23 52W H $55
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$35
MEDIAN
$46
MEAN
$47
HIGH
$56
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE COAG TAPE
COAG // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $49.83 | $47.36 | 2025-02-14 | $37.47 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $51.89 | $48.59 | 2025-02-06 | $38.71 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $46.95 | $45.30 | 2025-01-29 | $39.53 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $42.00 | — | 2025-01-17 | $40.36 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $36.24 | $39.12 | 2025-01-09 | $36.65 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $49.00 | $42.83 | 2024-12-18 | $35.83 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $39.94 | $41.59 | 2024-12-04 | $38.30 | -4.3% | 48% | C |